Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety, Tolerability, and Efficacy of Escalating Doses of BMS-986463 in Participants With Select Advanced Malignant Tumors.
Sponsor: Bristol-Myers Squibb
Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of escalating doses of BMS-986463 in participants with select advanced malignant tumors.
Official title: A Phase 1/1b First-in-human Study of BMS-986463 in Advanced Malignant Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
240
Start Date
2024-09-06
Completion Date
2028-12-19
Last Updated
2025-10-21
Healthy Volunteers
No
Conditions
Interventions
BMS-986463
Specified dose on specified days
Locations (16)
USC/Norris Comprehensive Cancer Center
Los Angeles, California, United States
Valkyrie Clinical Trials
Los Angeles, California, United States
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, United States
Local Institution - 0045
Columbus, Ohio, United States
Local Institution - 0046
Dallas, Texas, United States
BC Cancer Vancouver
Vancouver, British Columbia, Canada
Princess Margaret Cancer Centre
Toronto, Ontario, Canada
Centre Hospitalier de l'Université de Montréal
Montreal, Quebec, Canada
Jewish General Hospital
Montreal, Quebec, Canada
Local Institution - 0031
Villejuif, Val-de-Marne, France
Local Institution - 0036
Borddeaux Cedex, France
Local Institution - 0035
Lyon, France
Local Institution - 0032
Rozzano, Milano, Italy
Local Institution - 0033
Milan, Italy
Local Institution - 0041
Avda.Pio XII 36,, Spain
Local Institution - 0042
Barcelona, Spain